A pyrene-based HDAC inhibitor for dual-action therapy of breast cancer

Qizhang Li; Xing Lu; Yuanli Yang; Tianyu Li; Xuehua Chen; Rongmiao Yuan; Xin Ding; Silong Zhang; Huan He

doi:10.1039/D5CC01722J

You do not have JavaScript enabled. Please enable JavaScript to access the full features of the site or access our non-JavaScript page.

A pyrene-based HDAC inhibitor for dual-action therapy of breast cancer†

Qizhang Li,^a Xing Lu,^a Yuanli Yang,^a Tianyu Li,^b Xuehua Chen,^a Rongmiao Yuan,^a Xin Ding,*^b Silong Zhang

*^a and Huan He

*^a

Author affiliations

* Corresponding authors

^a Key Laboratory of Plant Resource Conservation and Germplasm Innovation in Mountainous Region (Ministry of Education), Guizhou Provincial Key Laboratory of Innovation and Manufacturing for Pharmaceuticals, Guizhou University, Guiyang 550025, Guizhou Province, P. R. China
E-mail: silongzhang@whu.edu.cn, ivy@whu.edu.cn

^b Hubei Key Laboratory of Pollutant Analysis & Reuse Technology, Hubei Normal University, Huangshi 435002, P. R. China
E-mail: dingx@hbnu.edu.cn

Abstract

Here we report PySAHA, a multifunctional HDAC inhibitor, which can uniquely degrade HDACs within cells via a hydrophobic tagging mechanism, and also possesses photodynamic therapeutic activity. The synergistic interplay of these dual functionalities results in potent anti-breast cancer efficacy.

Download options Please wait...

Supplementary files

Supplementary information PDF (1679K)

Article information

DOI: https://doi.org/10.1039/D5CC01722J
Article type: Communication
Submitted: 27 3月 2025
Accepted: 25 5月 2025
First published: 05 6月 2025

Download Citation

Chem. Commun., 2025, Advance Article

Permissions

Request permissions

A pyrene-based HDAC inhibitor for dual-action therapy of breast cancer

Q. Li, X. Lu, Y. Yang, T. Li, X. Chen, R. Yuan, X. Ding, S. Zhang and H. He, Chem. Commun., 2025, Advance Article , DOI: 10.1039/D5CC01722J

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Chemical Communications

A pyrene-based HDAC inhibitor for dual-action therapy of breast cancer†

Abstract

Supplementary files

Article information

Download Citation

Permissions

A pyrene-based HDAC inhibitor for dual-action therapy of breast cancer

Social activity

Search articles by author

Spotlight

Advertisements